Fever During Anti-integrin Therapy: New Immunodeficiency

  • Eleonora Bonfanti Department of Internal Medicine, "Santa Croce e Carle" Hospital, Cuneo
  • Christian Bracco Department of Internal Medicine, "Santa Croce e Carle" Hospital, Cuneo, Italy
  • Paolo Biancheri Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich, United Kingdom
  • Andrea Falcetta Department of Internal Medicine, "Santa Croce e Carle" Hospital, Cuneo, Italy
  • Marco Badinella Martini Department of Internal Medicine, "Santa Croce e Carle" Hospital, Cuneo, Italy
  • Remo Melchio Department of Internal Medicine, "Santa Croce e Carle" Hospital, Cuneo, Italy

Keywords

Vedolizumab, cytomegalovirus, ulcerative colitis

Abstract

Background: The causes of inflammatory bowel disease (IBD) have not yet been clearly elucidated, but it is known that genetic susceptibility, altered gut microbiota and environmental factors are all involved, and that a combination of these factors causes an inappropriate immune response, resulting in impaired intestinal barrier function. With regard to the treatment of IBD, the use of conventional immunosuppressive drugs has been complemented by more specific therapeutic agents, including biological drugs. Systemic immune suppression is a risk factor for cytomegalovirus (CMV) infection, which is associated with considerable morbidity and mortality in immunocompromised hosts.
Case Report: A 33-year-old male patient was admitted to our medical unit complaining of a 10-day history of fever, fatigue and headache. He had been suffering from ulcerative colitis and primary sclerosing cholangitis for five years and was currently being treated with azathioprine and vedolizumab. In the past he had already taken infliximab, adalimumab and golimumab without any clinical response. After the exclusion of systemic infectious diseases, his serology was consistent with a primary CMV infection. This was successfully treated with intravenous ganciclovir therapy.
Conclusion: Vedolizumab is an anti-integrin biological agent approved for IBD treatment. Its gut-selective mechanism of action would appear to increase its safety profile, however data on this are still limited. Moreover, it should always be remembered that IBD patients have an increased risk of CMV infection, both primary and reactivation, because of their concurrent immunosuppression.

VIEW THE ENTIRE ARTICLE

References

  • Roda G, Jharap B, Neeraj N, Colombel JF. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol 2016;7:e135.

  • Wyant T, Leach T, Sankoh S, Wang Y, Paolino J, Pasetti MF, et al. Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. Gut 2015;64:77-83.

  • Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011;140:1756-1767.

  • Beswick L, Ye B, Van Langenberg DR. Toward an algorithm for the diagnosis and management of CMV in patients with colitis. Inflamm Bowel Dis 2016;22:2966-2976.

  • Rowan C, Judge C, Cannon MD, Cullen G, Mulcahy HE, Ryan E, et al. Severe symptomatic primary CMV infection in inflammatory bowel disease patients with low population seroprevalence. Gastroenterol Res Pract 2018;2018:1029401.

  • Aratari A, Bossa F, Cappello M, Cassinotti A, Chiriatti A, Fiorino G, et al. Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Dig Liver Dis 2017;49:338-358.

  • Bonovas S, Fiorino G, Allocca M, Lytras T, Nikolopoulos GK, Peyrin-Biroulet L, et al. Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol 2016;14:1385-1397.

  • Meserve J, Aniwan S, Koliani-Pace JL, Shashi P, Weiss A, Faleck D, et al. Retrospective analysis of safety of vedolizumab in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2019;17:1533-1540.

  • Hommel C, Pillet S, Rahier J-F. Comment on: ‘Resolution of CMV infection in the bowel on vedolizumab therapy.’ J Crohn’s Colitis 2019 pii: jjz108. doi: 10.1093/ecco-jcc/jjz108.
  • Published: 2020-02-11

    Issue: Vol 7 No 3 (view)

    Section: Articles

    How to cite:
    1.
    Bonfanti E, Bracco C, Biancheri P, Falcetta A, Badinella Martini M, Melchio R. Fever During Anti-integrin Therapy: New Immunodeficiency. EJCRIM [Internet]. 2020Feb.11 [cited 2020Sep.18];7(3). Available from: https://ejcrim.com/index.php/EJCRIM/article/view/1288